MRS-guided HDR brachytherapy boost to the dominant intraprostatic lesion in high risk localised prostate cancer

BMC Cancer

Volumn 10, Issue 1, 2010, Pages

  Kazi, Aleksandra ^a   Godwin, Guy ^b   Simpson, John ^b   Sasso, Giuseppe ^c,d  

^a TOWNSVILLE HOSPITAL   (Australia)

^b Auckland Radiation Oncology ^*  (New Zealand)

^c 'Centre Medical de Forcilles' PSPH Hospital   (France)

^d JAMES COOK UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BRACHYTHERAPY; CANCER CONTROL; CANCER LOCALIZATION; CANCER RISK; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; EFFECTIVE DOSE (RADIATION); EXTERNAL BEAM RADIOTHERAPY; FEASIBILITY STUDY; HUMAN; HUMAN TISSUE; MAGNETIC RESONANCE SPECTROSCOPY GUIDED HIGH DOSE RATE BRACHYTHERAPY; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROBABILITY; PROSTATE CANCER; PROSTATE VOLUME; RADIATION DOSE DISTRIBUTION; RADIATION DOSE ESCALATION; TREATMENT PLANNING; VOXEL BASED MORPHOMETRY; COMPUTER ASSISTED RADIOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSTATE TUMOR; RADIATION DOSE FRACTIONATION; RADIATION EXPOSURE; RECTUM; RELATIVE BIOLOGIC EFFECTIVENESS; TREATMENT OUTCOME; URETHRA;

DIAGNOSTIC AGENT;

BRACHYTHERAPY; DOSE FRACTIONATION; FEASIBILITY STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RECTUM; RELATIVE BIOLOGICAL EFFECTIVENESS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; URETHRA;

EID: 79952197931     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-472     Document Type: Article

References (25)

1. Kurhanewicz J, Vigneron DB, Hricak H, Narayan P, Carroll P, Nelson SJ: Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Radiology 1996, 198(3):795-805
2. Kaji Y, Kurhanewicz J, Hricak H, Sokolov DL, Huang LR, Nelson SJ, Vigneron DB: Localizing prostate cancer in the presence of postbiopsy changes on MR images: role of proton MR spectroscopic imaging. Radiology 1998, 206(3):785-90
3. Terris MK: Prostate biopsy strategies: past, present, and future. Urol Clin North Am 2002, 29(1):205-12, xi
4. Yu KK, Scheidler J, Hricak H, Vigneron DB, Zaloudek CJ, Males RG, Nelson SJ, Carroll PR, Kurhanewicz J: Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 1999, 213(2):481-8
5. Pickett B, Kurhanewicz J, Coakley F, Shinohara K, Fein B, Roach M: Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2004, 60(4):1047-55
6. Pickett B, Ten Haken RK, Kurhanewicz J, Qayyum A, Shinohara K, Fein B, Roach M: Time to metabolic atrophy after permanent prostate seed implantation based on magnetic resonance spectroscopic imaging. Int J Radiat Oncol Biol Phys 2004, 59(3):665-73
7. Zakian KL, Sircar K, Hricak H, Chen HN, Shukla-Dave A, Eberhardt S, Muruganandham M, Ebora L, Kattan MW, Reuter VE, Scardino PT, Koutcher JA: Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 2005, 234(3):804-14
8. Zaider M, Zelefsky MJ, Lee EK, Zakian KL, Amols HI, Dyke J, Cohen G, Hu Y, Endi AK, Chui C, Koutcher JA: Treatment planning for prostate implants using magnetic-resonance spectroscopy imaging. Int J Radiat Oncol Biol Phys 2000, 47(4):1085-96
9. DiBiase SJ, Hosseinzadeh K, Gullapalli RP, Jacobs SC, Naslund MJ, Sklar GN, Alexander RB, Yu C: Magnetic resonance spectroscopic imaging-guided brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2002, 52(2):429-38
10. Pickett B, Vigneault E, Kurhanewicz J, Verhey L, Roach M: Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy. Int J Radiat Oncol Biol Phys 1999, 44(4):921-9
11. Xia P, Pickett B, Vigneault E, Verhey LJ, Roach M: Forward or inversely planned segmental multileaf collimator IMRT and sequential tomotherapy to treat multiple dominant intraprostatic lesions of prostate cancer to 90 Gy. Int J Radiat Oncol Biol Phys 2001, 51(1):244-54
12. van Lin EN, Futterer JJ, Heijmink SW, van der Vight LP, Hoffmann AL, van Kollenburg P, Huisman HJ, Scheenen TW, Witjes JA, Leer JW, Barentsz JO, Visser AG: IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys 2006, 65(1):291-303
13. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M: AJCC Cancer Staging Manual. New York: Springer-Verlag, 6 2002, 444
14. Skala M, Berry M, Duchesne G, Gogna K, Tai KH, Turner S, Kneebone A, Rolfo A, Haworth A: Australian and New Zealand three-dimensional conformal radiation therapy consensus guidelines for prostate cancer. Australas Radiol 2004, 48(4):493-501
15. Brenner DJ: Hypofractionation for prostate cancer radiotherapy-what are the issues? Int J Radiat Oncol Biol Phys 2003, 57(4):912-4
16. Fowler J, Chappell R, Ritter M: Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 2001, 50(4):1021-31
17. Wang JZ, Guerrero M, Li XA: How low is the alpha/beta ratio for prostate cancer? Int J Radiat Oncol Biol Phys 2003, 55(1):194-203
18. Fowler JF: The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol 2005, 44(3):265-76
19. Nutting CM, Corbishley CM, Sanchez-Nieto B, Cosgrove VP, Webb S, Dearnaley DP: Potential improvements in the therapeutic ratio of prostate cancer irradiation: dose escalation of pathologically identified tumour nodules using intensity modulated radiotherapy. Br J Radiol 2002, 75(890):151-61
20. Pouliot J, Kim Y, Lessard E, Hsu IC, Vigneron DB, Kurhanewicz J: Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging. Int J Radiat Oncol Biol Phys 2004, 59(4):1196-207
21. Kaji Y, Wada A, Imaoka I, Matsuo M, Terachi T, Kobashi Y, Sugimura K, Fujii M, Maruyama K, Takizawa O: Proton two-dimensional chemical shift imaging for evaluation of prostate cancer: external surface coil vs. endorectal surface coil. J Magn Reson Imaging 2002, 16(6):697-706
22. Barendsen GW: Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys 1982, 8(11):1981-97
23. Stock RG, Stone NN, Cesaretti JA, Rosenstein BS: Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys 2006, 64(2):527-33
24. Elliott SP, Meng MV, Elkin EP, McAninch JW, Duchane J, Carroll PR: Incidence of urethral stricture after primary treatment for prostate cancer: data From CaPSURE. J Urol 2007, 178(2):529-34, discussion 534
25. Sartor AO, Hricak H, Wheeler TM, Coleman J, Penson DF, Carroll PR, Rubin MA, Scardino PT: Evaluating localized prostate cancer and identifying candidates for focal therapy. Urology 2008, 72(6 Suppl):S12-24